Nocturnal Asthma

No articles were found for this section.

Pearl: Definition, Classification and Nomenclature is a core element of this topic; weigh it against the sections above.

No articles were found for this section.

Pearl: Pathophysiology and Mechanism is a core element of this topic; weigh it against the sections above.

No articles were found for this section.

Pearl: Epidemiology, Etiology and Risk Factors is a core element of this topic; weigh it against the sections above.

The epidemiological data underscore that nocturnal symptoms are a common and clinically significant phenotype. The clinical presentation of nocturnal asthma is defined by a characteristic pattern of symptoms that worsen during sleep, often leading to sleep disruption and daytime impairment.

Presenting Symptoms

Nocturnal asthma typically presents with a combination of cough, wheeze, dyspnea, and chest tightness that occurs predominantly during sleep, most frequently in the early morning hours (2-4 AM). These symptoms are often the first sign of loss of asthma control and are associated with significant morbidity. In a cohort of children with mild-to-moderate persistent asthma, 72.2% experienced at least one nocturnal asthma symptom requiring albuterol (NASRA) over 48 weeks, and 24.3% had 13 or more such episodes ^[4]A1b. The majority (81.3%) of nocturnal symptoms occurred outside exacerbation periods, yet they were associated the next day with increased albuterol use (56.9% vs 18.1% of days; RR 2.3, 95% CI 2.2-2.4), school absence (5.0% vs 0.3%; RR 10.6, 95% CI 7.8-14.4), and doctor contact (3.7% vs 0.2%; RR 8.8, 95% CI 6.1-12.5) ^[4]A1b.

Sleep deprivation itself worsens nocturnal asthma. In a randomized crossover study, adolescents with asthma who slept 6.5 hours (short sleep) had an 8.4% decrease in overnight peak expiratory flow rate (PEFR) compared with a 10-hour sleep opportunity (P = 0.007), and reported more asthma symptoms interfering with activities ^[2]A1b. Small-airways dysfunction is a key contributor: a systematic review found that small-airways dysfunction associates with the presence of nocturnal asthma, worse asthma control, and more severe bronchial hyperresponsiveness ^[10]D5.

Nocturnal asthma symptoms are also a marker of more severe disease. A systematic review of 13 studies concluded that nocturnal asthma was consistently associated with worse symptom severity and poorer pulmonary function compared with non-nocturnal asthma ^[15]B2a. In a 17-year follow-up of adults with asthma, optimal asthma control (defined as no nocturnal symptoms, SABA use ≤2 times/week, and no exacerbations) was achieved in only about 40% of patients, and this proportion did not improve over time ^[20]B2b.

Physical Examination Findings

During an acute nocturnal episode, patients may exhibit tachypnea, use of accessory muscles, and wheezing on auscultation. Supine posture itself increases airway resistance: in a study of healthy volunteers, going from sitting to supine reduced functional residual capacity by approximately 1 liter and exaggerated the airway response to methacholine, associated with greater dyspnea ^[12]C4. Neural respiratory drive is measurably increased in nocturnal asthma. Using chest wall electromyography (EMGpara), patients with uncontrolled asthma had significantly higher respiratory effort (18.4% of maximum in the morning) compared with controlled asthma (8.1%) and normal subjects (4.9%) ^[6]C4. Patients with nocturnal asthma and comorbid obstructive sleep apnea (OSA) may have physical signs such as obesity, large neck circumference (mean 36.6 cm vs 34.8 cm in those without OSA), and lower minimum oxygen saturation (80.7% vs 87.2%) ^[14]C4.

Phenotypic Variants

Two overlapping phenotypes are recognized:

Importantly, OSA risk is associated with nocturnal asthma symptoms (OR 2.6, 95% CI 1.3-5.0) but not with asthma in the absence of nocturnal symptoms, suggesting that some nocturnal symptoms perceived as asthma may actually be OSA ^[13]B2c. CPAP therapy for 3 months in patients with both conditions improved daytime sleepiness and quality of life but did not enhance asthma control ^[14]C4.

Red Flags

• Frequent nocturnal awakenings (≥2 per week) despite controller therapy
• Need for rescue albuterol during the night
• Symptoms despite optimal therapy (moderate-to-high dose ICS/LABA)
• Presence of OSA symptoms (snoring, witnessed apneas, daytime sleepiness, obesity, large neck circumference)
• Left lateral decubitus position during sleep: a prospective study found that sleeping in the left lateral decubitus position was independently associated with asthma exacerbation over one year ^[11]B2b

Nocturnal asthma is associated with increased risk of exacerbations and worse quality of life ^[15]B2a. Patients presenting to the emergency department at night have a shorter duration of symptoms (≤3 hours: 25.9% vs 13.4%) but no difference in hospitalization risk compared with daytime presentations ^[17]B3b.

Atypical Presentations

• Nocturnal cough as the sole symptom: may be mistaken for postnasal drip, gastroesophageal reflux, or pertussis
• Symptoms attributed to anxiety or panic attacks
• Underreporting in children: children may not spontaneously report nocturnal symptoms; parents may note restless sleep, coughing, or daytime somnolence ^[4]A1b
• Nocturnal asthma in the elderly: may present with dyspnea on awakening rather than classic wheeze

Pearl: In any patient with nocturnal asthma symptoms despite adequate controller therapy, screen for obstructive sleep apnea using the STOP-Bang questionnaire, up to one-third will have significant OSA, and treating the sleep disorder improves daytime symptoms even if asthma control does not change ^{[13]B2c[14]C4}.

The clinical suspicion of nocturnal asthma, raised by a history of nighttime awakening, cough, or dyspnea, must be confirmed by objective evidence of variable airflow obstruction, ideally captured during the sleep period. Because standard spirometry performed in the clinic may be normal, a diurnal peak expiratory flow (PEF) diary is the cornerstone of diagnosis.

Spirometry and Bronchodilator Reversibility

Spirometry should be performed in all patients with suspected asthma. A post-bronchodilator improvement in FEV₁ ≥12% and ≥200 mL is diagnostic of reversible airflow obstruction. However, spirometry alone is insufficient for nocturnal asthma: in a cohort of 166 patients, 43% of those without airflow obstruction (FEV₁/FVC >0.70) had nocturnal symptoms, and only non-spirometric markers of small airway dysfunction (SAD) were elevated in this subgroup ^[25]C4. Thus, normal spirometry does not exclude nocturnal asthma.

Diurnal Peak Expiratory Flow Monitoring

A twice-daily PEF diary (on waking and before bedtime) is the most practical way to capture the nocturnal dip. A nocturnal fall in PEF >15% is a widely used threshold to define nocturnal asthma ^[21]C4. In controlled asthma, diurnal PEF variability is <20%; in uncontrolled asthma, it exceeds 20% ^[6]C4. The overnight decrease in PEFR is both a marker of nocturnal asthma and a predictor of daytime airflow limitation ^[2]A1b.

Bronchial Provocation Testing

When spirometry and PEF monitoring are inconclusive, bronchial hyperresponsiveness (BHR) should be assessed. Methacholine and hypertonic saline (HS) are both used. Importantly, bronchial responsiveness to HS increases at night: the provocative dose causing a 20% FEV₁ drop (PD₂₀) was significantly lower at 4 AM (2.93 ± 4.74 mL) than at 4 PM (4.94 ± 6.77 mL, p = 0.002) ^[21]C4. Testing at the time of maximal symptoms may improve diagnostic yield. Small airway dysfunction, measured by impulse oscillometry (R5-R20, AX), lung volumes (RV%), or inert gas washout (LCI), is independently associated with nocturnal asthma and with more severe BHR, even when spirometry is normal ^[25]C4[26]C4.

Overnight Oximetry and Polysomnography

Nocturnal asthma is associated with lower mean oxygen saturation: 93.8% vs 94.3% in those without asthma (p = 0.01), an effect that persists after adjustment for age, BMI, and smoking ^[22]B2c. The presence of comorbid obstructive sleep apnea (OSA) further lowers saturation (92.5% vs 94.3% for wheeze alone, p < 0.01) ^[22]B2c. Polysomnography is indicated when OSA is suspected (snoring, witnessed apnea, obesity), as the two conditions frequently coexist ^{[23]B2c[24]D5}.

Differential Diagnosis

Nocturnal asthma shares features with several other sleep-related respiratory disorders. Key alternatives include:

• Obstructive sleep apnea (OSA): presents with snoring, observed apnea, and daytime sleepiness; confirmed by polysomnography (AHI ≥5 events/h). The overlap syndrome is common ^[24]D5.
• Gastroesophageal reflux disease (GERD): nocturnal cough or heartburn; pH monitoring may help.
• Vocal cord dysfunction: inspiratory stridor, normal spirometry, laryngoscopy shows adduction.
• Cardiac asthma: paroxysmal nocturnal dyspnea from heart failure; BNP, echocardiography.

A diagnostic algorithm integrating these steps is shown below.

Step 1: Twice-daily PEF diary. A nocturnal fall >15% confirms nocturnal asthma. Step 2: If PEF is normal, perform spirometry with bronchodilator. Step 3: If spirometry is non-diagnostic, proceed to bronchial provocation. Step 4: If provocation is negative, evaluate for SAD with non-spirometric techniques. Step 5: If all tests are negative, investigate alternative diagnoses.

Gold-Standard Test

There is no single gold-standard test for nocturnal asthma. The diagnosis rests on the combination of a compatible history and objective demonstration of variable airflow obstruction, with a documented nocturnal pattern. Diurnal PEF variability >20% ^[6]C4 and an overnight PEF drop >15% ^[21]C4 are the most widely accepted objective criteria in research.

Laboratory Studies

Routine labs are not diagnostic. Inflammatory markers (blood eosinophils, FeNO, sputum eosinophils) may be elevated in patients with nocturnal asthma but are not required for diagnosis ^[25]C4.

Pearl: When spirometry is normal in a patient with nocturnal symptoms, a PEF diary is the most sensitive bedside tool; a single overnight PEF drop >15% is sufficient to confirm the diagnosis and should prompt escalation of anti-inflammatory therapy, regardless of clinic spirometry.

Beyond establishing the diagnosis, the presence and frequency of nocturnal asthma symptoms serve as a critical marker of disease severity and a predictor of adverse outcomes. Multiple classification schemes have been used to grade nocturnal symptom burden, and these grades consistently correlate with worse lung function, increased morbidity, and higher risk of comorbid obstructive sleep apnea (OSA).

Severity Grading Using Nocturnal Symptoms

Nocturnal symptoms are incorporated into standard asthma control assessments, but specific grading systems have been developed for research. In the EPISONO study, participants were classified as having intermittent (53%) or persistent (47%) nocturnal asthma based on symptom frequency; those with persistent symptoms had higher BMI, worse lung function, and a higher apnea-hypopnea index (AHI) ^[23]B2c. Among children with mild-to-moderate persistent asthma, nocturnal asthma symptoms requiring albuterol (NASRAs) occurred in 72.2% of participants, with 24.3% experiencing 13 or more episodes over 48 weeks ^[4]A1b. In a cohort of 166 adults, 52% reported nocturnal symptoms at least once in the prior four weeks; 17% had frequent (≥1/week) and 35% infrequent symptoms ^[25]C4. Urban children with persistent asthma showed a similar distribution: 41% intermittent, 23% mild persistent, and 36% moderate-to-severe nocturnal symptoms ^[30]C4.

Risk Stratification for Exacerbations and Morbidity

Nocturnal symptoms are associated with significant next-day morbidity. In children, days preceded by NASRAs had higher rates of albuterol use (56.9% vs 18.1%; RR 2.3), school absence (5.0% vs 0.3%; RR 10.6), and doctor contact (3.7% vs 0.2%; RR 8.8) ^[4]A1b. However, nocturnal symptoms did not predict the onset of exacerbations ^[4]A1b. In adults, baseline asthma severity, Asthma Control Test (ACT) score, and sleeping in the left lateral decubitus (LLD) position were independently associated with exacerbation over one year ^[11]B2b. A systematic review confirmed that nocturnal asthma is consistently associated with worse symptom severity and poorer pulmonary function, though evidence for increased hospitalization rates was mixed ^[15]B2a. Nocturnal asthma also independently predicted poor asthma-related quality of life (p=0.046) ^[31]C4.

Identifying Comorbid Obstructive Sleep Apnea

OSA is highly prevalent in patients with nocturnal asthma. In one cohort, 81% of asthmatics had OSA (AHI>5) ^[11]B2b; another found 33.6% with AHI≥10 ^[14]C4. The EPISONO study reported a positive association between persistent nocturnal asthma and OSA ^[23]B2c. Importantly, OSA risk (STOP-Bang ≥3) was associated with nocturnal asthma-like symptoms even in the absence of current asthma (OR 2.6), suggesting that some nocturnal symptoms may be due to OSA rather than asthma ^[13]B2c. CPAP therapy for 3 months improved daytime sleepiness and quality of life but did not enhance asthma control ^[14]C4. Therefore, patients with nocturnal asthma symptoms should be screened for OSA, especially if they have snoring, obesity, or large neck circumference.

Prognostic Implications of Small Airway Dysfunction

Small airway dysfunction (SAD) is closely linked to nocturnal asthma. In a study of 166 patients, the odds of nocturnal asthma correlated with all non-spirometric measures of SAD (e.g., lung clearance index, residual volume) but not with FEV1 or FEV1/FVC ^[25]C4. Patients with frequent nocturnal asthma had more severe SAD, worse asthma control, increased fatigue, and reduced quality of life ^[25]C4. Even in the absence of airflow obstruction, nearly 43% of patients had nocturnal asthma, and markers of air trapping and ventilation heterogeneity were elevated ^[25]C4. Bronchial hyperresponsiveness to mannitol was also lower in children with nocturnal asthma symptoms (PD15 490 mg vs 635 mg, p=0.03), suggesting that BHR testing may serve as a monitoring tool ^[18]B2b. Circadian variation in bronchial responsiveness to hypertonic saline has been demonstrated, with increased responsiveness at 4 AM compared to 4 PM ^[21]C4.

Pearl: Nocturnal asthma symptoms are a marker of disease severity and poor control, but they do not reliably predict exacerbations; instead, they signal the need to assess for comorbid OSA and small airway dysfunction, which may require targeted therapy beyond standard spirometry-guided management.

No articles were found for this section.

Pearl: Acute Management and Exacerbation Rescue is a core element of this topic; weigh it against the sections above.

No articles were found for this section.

Pearl: Long-term and Definitive Management is a core element of this topic; weigh it against the sections above.

No articles were found for this section.

Pearl: History and Evolution of Treatment is a core element of this topic; weigh it against the sections above.

No articles were found for this section.

Pearl: Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) is a core element of this topic; weigh it against the sections above.

No articles were found for this section.

Pearl: Complications is a core element of this topic; weigh it against the sections above.

No articles were found for this section.

Pearl: Prognosis and Natural History is a core element of this topic; weigh it against the sections above.

Given the association between nocturnal asthma and more severe disease ^[15]B2a, special populations require tailored diagnostic and therapeutic approaches. The following subsections address key modifications for pediatrics, pregnancy, the elderly, and immunocompromised patients, based on the available evidence.

Pediatrics

Nocturnal asthma is prevalent in children: among urban children aged 4-10 years with persistent asthma, 36% had moderate-to-severe nocturnal symptoms, and the average total sleep quality score was 51 (above the clinically significant cutoff of 41), indicating pervasive sleep disturbances ^[30]C4. Worse nocturnal symptoms were associated with poorer parent quality of life and fewer nights with sufficient sleep ^[30]C4.

• Diagnostic considerations: The mannitol challenge can monitor bronchial hyperresponsiveness in children aged 4-16 years. The provocative dose to induce a 15% drop in FEV1 (PD15) was significantly lower in children with nocturnal asthma symptoms (490 mg vs. 635 mg; p = 0.03), suggesting that this test may reflect therapy response ^[18]B2b.
• Treatment modifications: In preschoolers <5 years (mean age 2.87 years), combination fluticasone propionate plus salmeterol (FP/SA) was well-tolerated and highly effective. After a mean treatment duration of 12.45 months, nocturnal asthma decreased by 81% (from 33.7% to 6.4%; p < 0.001), with similar reductions in hospitalization rates and exercise-induced asthma ^[34]C4. No major drug-related side-effects occurred ^[34]C4.
• Sleep hygiene intervention: Among adolescents with asthma, higher sleep hygiene scores were associated with better sleep quality (β = 0.377, p = 0.015), higher school-related health-related quality of life (β = 0.321, p = 0.040), and better sustained attention (β = 0.327, p = 0.045) ^[33]C4. Sleep hygiene should be assessed and addressed as a modifiable factor.
• Extrafine ICS: Children are among the phenotypes in which small airways appear more affected; extrafine inhaled corticosteroid formulations may offer additional benefits for nocturnal asthma control ^[35]D5.

Pregnancy

The retrieved evidence does not include studies on nocturnal asthma in pregnancy. No teratogenicity data, delivery planning recommendations, or breastfeeding safety information specific to nocturnal asthma therapies are reported in the reviewed literature. In the absence of condition-specific data, management should follow general asthma-in-pregnancy principles: inhaled corticosteroids (e.g., budesonide) remain the preferred controller, with long-acting beta-agonists added if needed. Extrafine ICS formulations, which may improve small airways deposition ^[35]D5, have not been evaluated for safety in pregnancy in these studies. Clinicians should monitor for nocturnal symptoms and adjust therapy accordingly, recognizing that uncontrolled asthma poses greater fetal risk than standard medications.

Elderly

Elderly asthmatic patients are identified as a phenotype with greater small airways involvement ^[35]D5. Extrafine ICS formulations may be particularly beneficial in this group for achieving peripheral airway deposition and improving nocturnal asthma control ^[35]D5. No specific dose modifications or comorbidity interaction data are provided in the retrieved evidence; however, clinicians should review concomitant medications (e.g., beta-blockers, NSAIDs) that may exacerbate asthma. Pulmonary function thresholds for diagnosis should be interpreted with age-related changes in mind, though specific cutoffs are not reported in these studies.

Immunocompromised

The reviewed literature does not address nocturnal asthma in immunocompromised hosts. Management should adhere to standard asthma guidelines, with heightened attention to infection risk and potential drug interactions with immunosuppressive regimens. No specific treatment modifications are supported by the available evidence.

Pearl: In pediatric nocturnal asthma, combination ICS/LABA therapy (fluticasone/salmeterol) is safe and highly effective in children as young as 2 years, reducing nocturnal symptoms by over 80% ^[34]C4; sleep hygiene interventions should be integrated into management to improve daytime function ^[33]C4.

No articles were found for this section.

Pearl: Prevention, Screening & Surveillance is a core element of this topic; weigh it against the sections above.